Andrew Miller

Balancer
DISC Type : S

Chairman of the Board at Progentos Therapeutics

Greater Boston, United States

Overview

Dr. Andrew Miller is a highly accomplished biopharmaceutical executive who founded Karuna Therapeutics and invented COBENFY (KarXT), the first new class of schizophrenia treatment in decades. A PhD graduate from MIT, he is now Chairman of the Board at Progentos Therapeutics, which focuses on therapies for Multiple Sclerosis.

Outside of his direct research, Dr. Miller is passionate about fostering innovation in mental health. He actively supports and mentors startups in the field through his work with accelerator programs like One Mind. He recently had the honor of attending the TIME100 Next Gala and walking his first red carpet.

Unique fact: To create the groundbreaking drug COBENFY, he tested over 7, 000 compounds, ultimately finding success with an "out-of-the-box approach" that combined a psychiatric drug with a treatment for overactive bladders.

Personality Overview

Empathetic

Formal Mannered

Good Listener

They are confident about making long-term decisions.  Even if it takes time, they prefer following the process. They are polite and respectful but practical.

Topics They Care About

Mental Health Treatment
He invented KarXT/COBENFY, the first new class of schizophrenia treatment in over 30 years, and is passionate about elevating the dialogue around mental illness.
Neurodegenerative Diseases
As Chairman of Progentos Therapeutics, he is currently focused on developing first-in-class, disease-modifying therapeutics for Multiple Sclerosis (MS) and other demyelinating diseases.
Biotech Entrepreneurship
He founded Karuna Therapeutics, grew it from one to over 350 employees, and raised ~$2B prior to its $14B acquisition. He now advises several venture capital firms.

Media Appearances

Andrew has no verified media appearances

Work History

Chairman of the Board at Progentos Therapeutics
Advisor at GV (Google Ventures)
Advisor at General Atlantic
Advisor at Longwood Fund
Advisor at Vida Ventures, LLC

Education

2003 - 2008
Doctor of Philosophy (PhD) from Massachusetts Institute of Technology
1999 - 2003
Bachelor's degree from University of Illinois Urbana-Champaign

More Information

Social Presence :

Prographics :

Exp : N/A Location : Greater Boston, United States Job Level : N/A Designation : Chairman of the Board at Progentos Therapeutics
URL has been copied!

Insights For Selling To Andrew

During A Call Or A Meeting

DO's

  • Actively address their concerns around change, risk, and acceptance by users
  • Share information about the process and how it would address all concerns
  • Be very observant about how they perceive the risk in the decision

DONT's

  • Skip mentioning details that are confusing
  • Don’t push them for a no, take the lack of yes as a no after a certain point
  • Don’t brush off their concerns, their comfort with you will go down

When Cold Calling

When Writing An Email

While Negotiating & Closing

    The secret to closing fast with Andrew is

  • Low-risk, adoption by others and strong collaterals matter the most to them.
  • Will you ever get a clear answer from Andrew

  • They never like to say no directly, they postpone the decisions or just go silent.

Insights For Deal Planning

    How fast (or slow) will Andrew move?

  • They can be very slow in making decisions.
  • Can Andrew take some risk or not?

  • They are very likely to play it safe rather than taking risk.

You And Andrew

Personality Compatibility


More Profiles

Discover additional public profiles from our index.

Search more profiles

Looking for someone else? Search here for anyone.

Or visit Humantic AI to know more.